Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS Clinical research trials and A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS. A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS

A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS



A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS

For Condition: Cryptosporidiosis,HIV Infections
Status: Completed
Sponsor(s): Janssen Pharmaceutica ,
Synopsis: To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in AIDS patients who have been treated in the double-blind study # JRD 64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with cryptosporidial related diarrhea and who meet the inclusion and exclusion criteria of this protocol.
Details:
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 12 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Zidovudine (AZT). - Didanosine (ddI) allowed but discouraged, must have been stabilized on a constant dose for 3 weeks or more. - Aerosolized pentamidine. - Nystatin for control of oropharyngeal infections. Nystatin must not be taken within two hours of diclazuril. - Ganciclovir therapy only for CMV retinitis is permitted if the patient has been treated for at least 4 weeks prior to study entry and is stable on the drug. - Loperamide may be taken if patient has been on long term loperamide prior to study entry but should not be started during the course of this protocol. Patients must have the following: Written informed consent given after the purpose and nature of the study, as well as the possible adverse effects related to the study drug, have been explained. - Be willing and able to return for all subsequent weekly visits and the two week visit post completion of therapy (follow-up). Prior Medication: Allowed: - Diclazuril. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Uncontrolled vomiting. - Estimated survival less than 28 days. - Other treatable enteric pathogens must be treated and eradicated prior to study entry. Concurrent Medication: Excluded: - Amphotericin B. - Other antibiotics or antiprotozoal drugs. - Other investigational agents. - Trimethoprim/sulfamethoxazole. - Antifungal medications except nystatin. - Ganciclovir for other than Cytomegalovirus (CMV) retinitis. - Antidiarrheal agents other than patients on long term loperamide prior to study entry. Patients with the following are excluded: - Undependable in following the instructions of the investigator. - Not able to swallow capsules. - Uncontrolled vomiting. - Estimated survival less than 28 days. Prior Medication: Excluded: - Diclazuril within 2 weeks of study entry.
Total Enrollment: 

Location and Contact Information:

Saint Luke's - Roosevelt Hosp Ctr
New York City,  New York,  10025
United States
 

Cornell Univ Med Ctr
New York City,  New York,  10021
United States
 

Bellevue Hosp / New York Univ Med Ctr
New York City,  New York,  10016
United States
 


Additional Information:
Study ID Numbers:  038B;  JRD 64,433/1102
Study Start Date: 
Record last reviewed: July 1990
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002278

Other Hiv Infections Studies:
1. A Study to Compare the Safety and Effectiveness of Indinavir Combined with Stavudine and Lamivudine

2. Drug Interactions of Amprenavir and Efavirenz, in Combination with a Second Protease Inhibitor, in HIV-Negative Volunteers

3. Nerve Damage in Patients with HIV Infection Who Have Been Treated with Anti-HIV Drugs

4. Effects of Therapeutic HIV Vaccination on Control of HIV after Discontinuation of Anti-HIV Drugs

5. A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis

Related Studies:

Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS
Modify your Search

  Other HIV Infections Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103